via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announces that it has been featured
in a broadcast via NetworkNewsAudio (“NNA”), a solution that
delivers additional visibility, recognition and brand awareness in
the investment community via distribution to thousands of
syndication points. The audio press release covers CNS
Pharmaceuticals’ recent announcement of dosing of the first
patients in its Berubicin clinical development program for the
treatment of recurrent glioblastoma multiforme (GBM), one of the
most aggressive types of brain cancer.
To hear the audio production, visit:
https://www.nnw.fm/imIah
To read the original press release, visit:
https://nnw.fm/QlM2S
“I am extremely pleased with the progress made to-date in this
potentially pivotal trial. Our team has been working intensely to
open sites in the U.S. and in Europe, understanding where we can
best advance this important study,” John Climaco, CEO of CNS
Pharmaceuticals, stated in the news release. “With hundreds of
potentially competing GBM trials currently enrolling patients, the
fact that we've been able to bring these initial sites on-line and
get patients enrolled and dosed not only supports our strategic
evaluation and selection, but also allows our data demonstrating
Berubicin's potential effectiveness to continue to convince the
medical community that we have a new drug with impressive
potential. With the de-risked profile of Berubicin, its mechanism
of action, history of development, encouraging Phase 1 data, and
safety in study design, I am personally more optimistic about our
work than at any time since joining the company.”
Berubicin is a novel anthracycline and the first anthracycline
to appear to cross the blood-brain barrier currently being
evaluated in a global potentially pivotal study evaluating its
efficacy and safety. The potentially pivotal trial is an adaptive,
multicenter, open-label, randomized and controlled study in adult
patients with recurrent glioblastoma multiforme (WHO Grade IV)
after failure of standard first-line therapy. Approximately 243
patients with GBM after failure of standard first line therapy will
be randomized in a 2:1 ratio to receive Berubicin or lomustine for
the evaluation of Overall Survival, the primary endpoint of the
study. Overall Survival is a rigorous endpoint that the U.S. Food
and Drug Administration (FDA) has recognized as a basis for
approval of oncology drugs when a statistically significant
improvement can be shown relative to a randomized control arm.
In the Phase 1 clinical trial previously conducted evaluating
Berubicin in patients with previously treated disease, 44% of the
patients showed clinical benefit (49% of the Avastin-naïve patient
population), with the demonstration that it was effective based on
this patient population with a dismal median survival rate of only
14.6 months from diagnosis. One patient in the Phase 1 study had a
durable Complete Response (CR, a demonstrated lack of detectable
cancer cells) that has continued for 14 years, and another patient
had a durable partial response, with others showing substantial
stabilization of disease. Additionally, the novel anthracycline
agent Berubicin appears to have a toxicity profile consistent with
that of other anthracyclines and demonstrates activity as
monotherapy for recurrent glioblastoma multiforme. Berubicin has
side effects that are able to be effectively treated and
managed.
For more information about the potentially pivotal Berubicin
trial, visit clinicaltrials.gov and reference identifier
NCT04762069.
About Berubicin
Berubicin is an anthracycline, a class of anticancer agents that
are among the most powerful chemotherapy drugs and effective
against more types of cancer than any other class of
chemotherapeutic agents. Anthracyclines are designed to utilize
natural processes to induce deoxyribonucleic acid (DNA) damage in
targeted cancer cells by interfering with the action of
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin treatment of brain cancer patients appeared to
demonstrate positive responses that include one durable complete
response in a Phase 1 human clinical trial conducted by Reata
Pharmaceuticals Inc. Berubicin was developed by Dr. Waldemar
Priebe, Professor of Medicinal Chemistry at The University of Texas
MD Anderson Cancer Center.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the company is advancing the development of its
WP1244 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the company on Twitter, Facebook and LinkedIn.
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within IBN
(InvestorBrandNetwork), allows you to sit back and listen to market
updates, CEO interviews and AudioPressRelease (“APR”) productions.
These audio clips provide snapshots of position, opportunity and
momentum. NNA can assist by cutting through the overload of
information in today's market, while bringing its clients
unparalleled visibility, recognition and brand awareness. IBN is
where news, content and information converge. IBN is a
comprehensive provider of news aggregation and syndication,
enhanced press release services and a full array of social
communication solutions. As a multifaceted financial news and
distribution company with an extensive team of journalists and
writers, IBN has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of 5,000+ key syndication outlets
across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the IBN website,
applicable to all content provided by IBN wherever published or
re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Company's
cash runway to extend until Q2 2022 and the timing of patient
dosing to commence. These statements relate to future events,
future expectations, plans and prospects. Although CNS believes the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Apr 2023 to Apr 2024